Skip to main content

Anti-Rheumatic Rx

RheumNow Podcast – Mistakes with Steroids

Apr 08, 2021

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Read Article

GLP-1 Therapy in Knee Osteoarthritis

Apr 08, 2021

Knee osteoarthritis is best managed by weight loss, as the effects of most analgesic therapies have been marginal and debatable. The use of anti-diabetic glucagon-like peptide-1 therapies have demonstrated significant weight loss benefits; hence this trial evaluated the potential weight loss and

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

Reactogenicity Following mRNA COVID-19 Vaccines

Apr 06, 2021

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article

Cost Efficacy of Knee Replacement in Obese Osteoarthritis

Apr 05, 2021

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

Read Article

Rituximab in Systemic Sclerosis?

Apr 05, 2021

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Apr 02, 2021

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Read Article

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Apr 01, 2021

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.



Janus kinase

Read Article

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Mar 31, 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.



Data derived from the retrospective

Read Article

Aortic Calcification and Lumbar Fracture Risk in Older Men

Mar 30, 2021

Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture in

Read Article

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Mar 26, 2021

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.




  1. Analysis of CPRD registry and 15,670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY and half that

Read Article
Analysis of CPRD registry and 15670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY; half that after Yr 1 (22 & 2.84). D/C for severe labs was 1 in 169 Yr1 & 1 in 352 per year after https://t.co/Dx91YqjplT

Dr. John Cush @RheumNow( View Tweet )

Mar 26, 2021
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo

Dr. John Cush @RheumNow( View Tweet )

Mar 25, 2021

FDA Panel Rejects Tanezumab for Osteoarthritis

Mar 25, 2021

A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).



Tanezumab (TAN) has been developed by Pfizer and Eli Lilly over the

Read Article
News Feature: Safety of Paternal DMARD or Biologic Use https://t.co/9jCNJ9rHYF https://t.co/SIRPcPQxyB
Dr. John Cush @RheumNow( View Tweet )
Mar 25, 2021
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
Mar 25, 2021

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

Mar 24, 2021

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA. Several noteworthy ones were

Read Article

Safety of Paternal DMARD or Biologic Use

Mar 22, 2021

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

Mar 22, 2021

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

Read Article

Liver Management in Rheumatoid Arthritis - RNL2021 Highlight

Mar 22, 2021

While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr. Stanley Cohen detailed many issues

Read Article

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

Mar 19, 2021

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article
NAFLD, NASH and Risks with DMARDs and MTX https://t.co/LYV9WycEjz https://t.co/Vx0jvhjCsd
Dr. John Cush @RheumNow( View Tweet )
Mar 19, 2021

RheumNow Podcast – Great Associations (3.19.2021)

Mar 18, 2021

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article

Are You a Super Rheum?

Mar 18, 2021

Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective

Read Article

Apremilast Equals MTX in Palmoplantar Psoriasis

Mar 18, 2021

Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.

Read Article
×